Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Fougeray

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
BJU International|September 9, 2014
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinomaGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Colorectal Cancer|November 8, 2017
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and WalesAsh Bullement, Stuart Underhill, Ronan Fougeray, et al.
Statistics in Medicine|September 20, 2021
A Bayesian approach for event predictions in clinical trials with time-to-event outcomesPaul Aubel, Marine Antigny, Ronan Fougeray, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2012
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxelMassimo Di Maio, Maciej Krzakowski, Ronan Fougeray, et al.
Breast (Edinburgh, Scotland)|December 1, 2012
Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancerMaria Blasinska-Morawiec, Nicole Tubiana-Mathieu, Ronan Fougeray, et al.
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
Future Oncology (London, England)|January 10, 2020
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study designThierry André, Mark Saunders, Akira Kanehisa, et al.
Future Oncology (London, England)|April 28, 2023
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancersLeanne Hamerton, Kelly Gomes, Ronan Fougeray, et al.
ESMO Open|December 7, 2017
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancerJosep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2019
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancerGuillem Argilés, Thierry André, Antoine Hollebecque, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
BJU International|September 9, 2014
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinomaGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Colorectal Cancer|November 8, 2017
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and WalesAsh Bullement, Stuart Underhill, Ronan Fougeray, et al.
Statistics in Medicine|September 20, 2021
A Bayesian approach for event predictions in clinical trials with time-to-event outcomesPaul Aubel, Marine Antigny, Ronan Fougeray, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2012
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxelMassimo Di Maio, Maciej Krzakowski, Ronan Fougeray, et al.
Breast (Edinburgh, Scotland)|December 1, 2012
Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancerMaria Blasinska-Morawiec, Nicole Tubiana-Mathieu, Ronan Fougeray, et al.
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
Future Oncology (London, England)|January 10, 2020
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study designThierry André, Mark Saunders, Akira Kanehisa, et al.
Future Oncology (London, England)|April 28, 2023
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancersLeanne Hamerton, Kelly Gomes, Ronan Fougeray, et al.
ESMO Open|December 7, 2017
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancerJosep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2019
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancerGuillem Argilés, Thierry André, Antoine Hollebecque, et al.
Pageof 3